نبذة مختصرة : Patent ductus arteriosus (PDA) is a congenital heart disease caused by failure of the ductus arteriosus to close immediately after birth. PDA can cause hemodynamic disturbances in premature infants as well as increased morbidity and mortality. Therefore, it needs to be closed immediately. Closuring of the PDA can use ibuprofen as a cyclooxygenase (COX) inhibitor, however, there are potential side effects. Paracetamol can be used as an alternative that acts as a peroxidase (POX) inhibitor with few side effects. This study aimed to compare the efficacy of paracetamol and ibuprofen on PDA closure in premature infants. This was a literature review, using four databases, such as Pubmed, ClinicalKey, Cochrane and ScienceDirect. The keywords used were paracetamol AND ibuprofen AND patent ductus arteriosus AND preterm AND newborn. Selection with inclusion and exclusion criteria obtained 13 articles. Paracetamol was as effective as ibuprofen for PDA closure therapy in premature infants. Paracetamol was safer than ibuprofen due to ibuprofen’s side effects. In conclusion, paracetamol is as effective as ibuprofen and is safer to be used in PDA closure therapy in premature babies.Keywords: paracetamol; ibuprofen; patent ductus arteriosus; preterm; newborn Abstrak: Patent ductus arteriosus (PDA) adalah penyakit jantung kongenital akibat gagalnya ductus arteriosus untuk menutup segera setelah lahir. PDA dapat menyebabkan gangguan hemodinamika pada bayi prematur, serta meningkatkan morbiditas dan mortalitas sehingga perlu segera ditutup. Penutupan PDA dapat menggunakan ibuprofen sebagai penghambat cyclo oxygenase (COX), namun terdapat efek samping potensial yang ditimbulkan. Parasetamol dapat digunakan sebagai alternatif yang bekerja menghambat peroksidase (POX) dengan sedikit efek samping. Penelitian ini bertujuan untuk membandingkan efikasi parasetamol dan ibuprofen untuk penutupan PDA pada bayi prematur. Penelitian ini berbentuk literature review, menggunakan empat database yaitu Pubmed, ClinicalKey, Cochrane ...
No Comments.